0000899243-20-017182.txt : 20200618 0000899243-20-017182.hdr.sgml : 20200618 20200618205115 ACCESSION NUMBER: 0000899243-20-017182 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20200618 FILED AS OF DATE: 20200618 DATE AS OF CHANGE: 20200618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NEUMANN CLARKE CENTRAL INDEX KEY: 0001321466 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 20974027 MAIL ADDRESS: STREET 1: 3595 JOHN HOPKINS CT CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER NAME: FORMER CONFORMED NAME: Neumann Clarke DATE OF NAME CHANGE: 20050323 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PROGENITY, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2020-06-18 0 0001580063 PROGENITY, INC. PROG 0001321466 NEUMANN CLARKE C/O PROGENITY, INC. 4330 LA JOLLA VILLAGE DRIVE, SUITE 200 SAN DIEGO CA 92122 0 1 0 0 General Counsel and Secretary Common Stock 34154 D Stock Option (Right to Buy) 6.49 2024-09-10 Common Stock 25898 D Stock Option (Right to Buy) 10.75 2025-02-01 Common Stock 9711 D Stock Option (Right to Buy) 12.54 2026-02-24 Common Stock 9711 D Stock Option (Right to Buy) 9.88 2027-02-23 Common Stock 19423 D Stock Option (Right to Buy) 9.88 2028-02-22 Common Stock 6474 D Stock Option (Right to Buy) 9.88 2029-04-15 Common Stock 19423 D Stock Option (Right to Buy) 9.76 2030-03-04 Common Stock 34800 D Stock Option (Right to Buy) 9.76 2030-03-04 Common Stock 6428 D Consists of 34,154 restricted stock units ("RSUs"), 4,720 of which have vested. Subject to the Reporting Person's continued service to the Issuer, (i) 3,806 RSUs will vest on March 4, 2021, and (ii) 4,350 RSUs will vest on May 15, 2021. All other unvested RSUs will vest in semi-annual installments, subject to the Reporting Person's continued service to the Issuer, (i) beginning on February 15, 2021 and ending on February 15, 2022 for 1,349 RSUs, (ii) beginning on February 15, 2021 and ending on August 15, 2023 for 6,879 RSUs and (iii) beginning on November 15, 2021 and ending on May 15, 2024 for 13,050 RSUs. This option represents the right to purchase 25,898 shares of the Issuer's common stock, all of which have vested. This option represents the right to purchase 9,711 shares of the Issuer's common stock, all of which have vested. This option represents the right to purchase 9,711 shares of the Issuer's common stock, all of which have vested. This option represents the right to purchase a total of 19,423 shares of the Issuer's common stock, 15,781 of which have vested, with the remaining shares vesting in equal monthly installments through February 23, 2021, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase a total of 6,474 shares of the Issuer's common stock, 3,776 of which have vested, with the remaining shares vesting in equal monthly installments through February 22, 2022, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase a total of 19,423 shares of the Issuer's common stock, 5,665 of which vested, with the remaining shares vesting in equal monthly installments through April 15, 2023, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase a total of 34,800 shares of the Issuer's common stock, 2,175 of which have vested, with the remaining shares vesting in equal monthly installments through March 15, 2024, subject to the Reporting Person's continued service to the Issuer. This option represents the right to purchase 6,428 shares of the Issuer's common stock, all of which have vested. Exhibit 24 - Power of Attorney /s/ Eric d'Esparbes, Attorney-in-fact for Clarke Neumann 2020-06-18 EX-24 2 attachment1.htm EX-24 DOCUMENT
                                 POWER OF ATTORNEY

    Know all by these presents that the undersigned hereby constitutes and
appoints each of Eric d'Esparbes, Regan Lauer and Will Pridgen, and any of
their substitutes, signing singly, as the undersigned's true and lawful
attorney-in-fact to:

1.  prepare, execute in the undersigned's name and on the undersigned's behalf,
    and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form
    ID, including amendments thereto, and any other document necessary or
    appropriate to obtain codes, passwords, and passphrases enabling the
    undersigned to make electronic filings with the SEC of reports require by
    the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

2.  execute for and on behalf of the undersigned, in the undersigned's capacity
    as a director and/or officer of Progenity, Inc. (the "Company"), Forms 3, 4,
    and 5 in accordance with Section 16(a) of the Securities Exchange Act of
    1934 and the rules thereunder;

3.  do and perform any and all acts for and on behalf of the undersigned which
    may be necessary or desirable to complete and execute any such Form 3, 4, or
    5, complete and execute any amendment or amendments thereto, and timely file
    such form with the SEC and any securities exchange or similar authority; and

4.  take any other action of any type whatsoever in connection with the
    foregoing which, in the opinion of such attorney-in-fact, may be of benefit
    to, in the best interest of, or legally required by, the undersigned, it
    being understood that the documents executed by such attorney-in-fact on
    behalf of the undersigned pursuant to this Power of Attorney shall be in
    such form and shall contain such terms and conditions as such attorney-in-
    fact may approve in such attorney-in-fact's discretion.

    The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned also ratifies hereby any action previously taken by
each attorney-in-fact that would have been authorized by this power of attorney
if it has been in effect at the time such action was taken.  The undersigned
acknowledges that each attorney-in-fact, in serving in such capacity at the
request of the undersigned, is not assuming, nor is the Company assuming, any of
the undersigned's responsibilities to comply with Section 16 of the Securities
Exchange Act of 1934, as amended.

    This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to each
of the foregoing attorneys-in-fact.

    IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 15th day of June, 2020.


                                                    /s/ Clarke Neumann
                                                   -----------------------------